ArticleBMC ophthalmology2025
Real-world clinical insights and aqueous humor biomarker analysis of diabetic macular edema subtypes classified by OCT following intravitreal injections.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aimed to observe the morphological changes and visual outcomes in diabetic macular edema (DME) subtypes based on optical coherence tomography classification following intravitreal injection.
methodsNinety-four eyes from seventy-eight patients were enrolled between July 1, 2018, and June 30, 2023. Best-corrected visual acuity (BCVA), central subfield thickness, and morphological changes were examined at each follow-up visit. Aqueous humor samples were obtained before intravitreal injection of anti-vascular endothelial growth factor or cataract surgery. The inflammatory cytokine profile in the aqueous humor of each DME subtype was analyzed to explore potential contributions.
resultsThe BCVA in the diffuse retinal thickening group was significantly improved at the last follow-up (p = 0.006), but no significant change in central subfield thickness was observed. Conversely, the BCVA in the cystoid macular edema and serous retinal detachment groups did not significantly improve, although a significant reduction in central subfield thickness was observed in both groups at the final follow-up (both p < 0.05). Principal component analysis of proteomic data revealed clear segregation between samples from patients with different DME subtypes and those from the control group. 59 proteins were found to be significantly regulated in the diffuse retinal thickening group compared to those in the control group. Of these, 10 proteins were upregulated, whereas 49 were downregulated. In the cystoid macular edema group, 30 proteins were significantly regulated, with 8 proteins upregulated and 22 downregulated. In the serous retinal detachment group, 87 proteins showed significant changes: 24 exhibited increased expression and 63 decreased expression.
conclusionsThe diffuse retinal thickening subtype showed a better response and cystoid macular edema was the most common morphological subtype of DME after intravitreal injection treatment in real-world clinical observations. The variations in protein expression of aqueous humor suggested distinct pathological mechanisms for each DME subtype, laying the groundwork for more targeted treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.